Cellebration has the technology to develop autologous peripheral mononuclear cells (PBMC) into dendritic cells using the patient’s blood and tumor cells. At Cellebration, we offer Dendritic (DC) immunotherapy for solid tumors such as prostate, breast, hepato-cellular, renal, colon, colorectal, glio-blastoma multiforme, oral, lung, and ovarian.
The precursor cells are collected from patients in a highly sterile lab and infused back into the body through intravenous administration. The process is completely autologous, and the mature dendritic cells develop antitumor activity through effector T cells that multiply in number and interact and directly kill tumor cells.
At Cellebration, we have mastered the technology for isolating the maximum number of viable stem cells from the autologous sources of your own body to treat various cancers. These cells are administered through intravenous administration after a considerable analysis of each patient’s unique history.
In this delivery mode, cells are infused into the peripheral veins to expand blood volumes in the system, to ensure that the maximum number of cells are reaching the targeted area.
Thus, with our highly specialized approach, it is now possible to obtain noticeable improvements in patients with cancer as well as improving functional abilities.